Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Current Investments (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Cash & Current Investments for 7 consecutive years, with $67.2 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 33.2% year-over-year to $67.2 million; the TTM value through Mar 2026 reached $67.2 million, down 33.2%, while the annual FY2025 figure was $71.9 million, 36.07% down from the prior year.
  • Cash & Current Investments hit $67.2 million in Q1 2026 for Barinthus Biotherapeutics, down from $71.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $200.6 million in Q1 2022 and bottomed at $67.2 million in Q1 2026.
  • Average Cash & Current Investments over 5 years is $136.3 million, with a median of $123.9 million recorded in 2024.
  • Year-over-year, Cash & Current Investments rose 28.64% in 2022 and then tumbled 36.07% in 2025.
  • Barinthus Biotherapeutics' Cash & Current Investments stood at $194.4 million in 2022, then fell by 17.53% to $160.3 million in 2023, then fell by 29.89% to $112.4 million in 2024, then crashed by 36.07% to $71.9 million in 2025, then decreased by 6.49% to $67.2 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $67.2 million, $71.9 million, and $75.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.